Azithromycin maintenance therapy in patients with cystic fibrosis: A dose advice based on a review of pharmacokinetics, efficacy, and side effects

Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection

(2011) Maurizio Renna et al.   JOURNAL OF CLINICAL INVESTIGATION

Effect of Azithromycin on Pulmonary Function in Patients With Cystic Fibrosis Uninfected With Pseudomonas aeruginosaA Randomized Controlled Trial

(2010) Lisa Saiman   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Rhabdomyolysis a result of azithromycin and statins: an unrecognized interaction

(2009) Johanna Strandell et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Long-term daily high and low doses of azithromycin in children with cystic fibrosis: A randomized controlled trial

(2009) S.K. Kabra et al.   Journal of Cystic Fibrosis

A low concentration of azithromycin inhibits the mRNA expression of N-acyl homoserine lactone synthesis enzymes, upstream of lasI or rhlI, in Pseudomonas aeruginosa

(2009) Toshihiro Kai et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS

Effects of prolonged use of azithromycin in patients with cystic fibrosis: A meta-analysis

(2009) D.F. Florescu et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS

Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection

(2008) Gratiana Steinkamp et al.   RESPIRATORY MEDICINE

Pharmacokinetics and sputum penetration of azithromycin during once weekly dosing in cystic fibrosis patients

(2007) E.B. Wilms et al.   Journal of Cystic Fibrosis